Enzychem Lifesciences Corporation (KOSDAQ:183490)

South Korea flag South Korea · Delayed Price · Currency is KRW
990.00
-27.00 (-2.65%)
Mar 25, 2026, 7:48 AM KST
-16.31%
Market Cap 76.86B
Revenue (ttm) 67.75B
Net Income (ttm) -18.13B
Shares Out 77.63M
EPS (ttm) -234.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 677,473
Average Volume 797,042
Open 1,003.00
Previous Close 1,017.00
Day's Range 986.00 - 1,012.00
52-Week Range 937.00 - 1,766.00
Beta 0.98
RSI 37.55
Earnings Date Apr 6, 2026

About Enzychem Lifesciences

Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea. [Read more]

Sector Healthcare
Founded 1999
Employees 130
Stock Exchange KOSDAQ
Ticker Symbol 183490
Full Company Profile

Financial Performance

In 2025, Enzychem Lifesciences's revenue was 67.75 billion, a decrease of -12.44% compared to the previous year's 77.38 billion. Losses were -18.13 billion, -17.98% less than in 2024.

Financial Statements

News

There is no news available yet.